thalidomide has been researched along with Dermatitis in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Dermatitis: Any inflammation of the skin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc." | 4.90 | [Progress in PDE4 targeted therapy for inflammatory diseases]. ( Song, SD; Tang, HF, 2014) |
| "Thalidomide and analogues are a class of immunomodulatory drugs or IMiDS." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| "Lenalidomide therapy was initiated, and the patient's skin condition improved after 6 weeks of treatment; however, his MDS progressed to acute myeloid leukemia, and he died shortly thereafter." | 1.37 | Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. ( Balin, SJ; Kurtin, PJ; Letendre, L; Pittelkow, MR; Wetter, DA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, SD | 1 |
| Tang, HF | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 1 |
| Sanchez, MR | 1 |
| Levis, WR | 1 |
| Balin, SJ | 1 |
| Wetter, DA | 1 |
| Kurtin, PJ | 1 |
| Letendre, L | 1 |
| Pittelkow, MR | 1 |
| Meier, F | 1 |
| Berner, D | 1 |
| Scherwitz, C | 1 |
| Rassner, G | 1 |
| Metzler, G | 1 |
| Stevens, RJ | 1 |
2 reviews available for thalidomide and Dermatitis
| Article | Year |
|---|---|
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; I | 2014 |
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
3 other studies available for thalidomide and Dermatitis
| Article | Year |
|---|---|
Myelodysplastic syndrome presenting as generalized granulomatous dermatitis.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Cell Count; Dermatitis; Disease Progression; Granuloma; H | 2011 |
[An unusual case of pyoderma gangrenosum with necrotizing granulomatous dermatitis].
Topics: Dermatitis; Granuloma; Humans; Male; Middle Aged; Pyoderma Gangrenosum; Rare Diseases; Thalidomide; | 2003 |
The place of thalidomide in the treatment of inflammatory disease.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Cytokines; | 1996 |